Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Early detection of stage I/II Lung Cancer by immunoassay of crosslinked plasma cell free nucleosomes

Friday, March 28, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses a paper presented at ELCC 2025, which details a new immunoassay for the early detection of stage I/II lung cancer using crosslinked plasma cell-free nucleosomes. The research is conducted by a team from Belgian Volition SRL and highlights the potential for improved prognostic capabilities in cancer diagnosis.
Price reaction · baseline $10.56 (2025-03-27 close) · hit pre-market · 4 other VNRX headline(s) in the window, move may be shared
day 0 close · peak
+4.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • The study presents a novel immunoassay for early lung cancer detection.
  • Focus on stage I/II lung cancer could lead to improved patient outcomes.
  • Research conducted by a reputable team at Belgian Volition SRL.

Full Press Release Details

Paper titled: Early detection of stage I/II Lung Cancer by immunoassay of crosslinked plasma cell free nucleosomes
J. MICALLEF, D. PAMART, B. CUVELIER, G. ROMMELAERE and M. HERZOG – R&D Department, Belgian Volition SRL, Isnes, Belgium
Presented at ELCC 2025

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What is the focus of the presented research?

The research focuses on early detection of stage I/II lung cancer.

Where was the study presented?

The study was presented at ELCC 2025.

Who conducted the research?

The research was conducted by the R&D Department at Belgian Volition SRL.

What method is used for detection?

An immunoassay of crosslinked plasma cell-free nucleosomes is used.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare lung cancer immunoassay early detection Belgian Volition
Last updated: Mar 28, 2025

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk